Other Events ·
Majority shareholder approves issuance of over 20% of shares at discount to Nasdaq price
SBFMSunshine Biopharma Inc.
Dr. Steve N. Slilaty, holding approximately 90% of voting power as CEO, approved a written consent to issue more than 20% of outstanding common stock at a deemed discount to the Nasdaq minimum price following a public offering that closed on October 9, 2026. The consent also authorized adjustments to Series D Warrant exercise prices and voluntary adjustments under warrant terms. This action bypasses standard shareholder voting requirements due to concentrated ownership. Sunshine Biopharma Inc. operates in the biotechnology industry.